• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞形成中的嘌呤能信号传导。

Purinergic signaling in giant cell formation.

作者信息

Lemaire Irma, Falzoni Simonetta, Adinolfi Elena

机构信息

Department of Cellular and Molecular Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.

出版信息

Front Biosci (Elite Ed). 2012 Jan 1;4(1):41-55. doi: 10.2741/359.

DOI:10.2741/359
PMID:22201854
Abstract

Cell fusion into multinucleated giant cells (MGC) is an essential process that contributes to many important biological mechanisms in mammalians. In the bone and immune system, macrophages are endowed with a remarkable potential for cell fusion events as evidenced by their propensity to fuse with other cells and between themselves during both normal processes and disease. Macrophage fusion is critical for the normal development of multinucleated osteoclasts, the cells responsible for bone resorption. Macrophages from various tissue compartments also undergo fusion into MGC, a hallmark of granulomatous inflammation. To date, the mechanisms underlying macrophage fusion remain poorly understood. Receptor-ligand interactions are thought to mediate this process and several lines of evidence implicate purinergic receptors in both osteoclast and MGC formation. Notably, the P2X7 receptor for extracellular ATP is expressed in osteoclasts and in many types of granulomas associated with infection, foreign body response and sterile inflammation. Through their ability to sense extracellular cues and ATP, a messenger of intercellular communication, purinergic receptors likely contribute to cell-cell interactions that result in macrophage fusion.

摘要

细胞融合形成多核巨细胞(MGC)是一个重要过程,它参与哺乳动物许多重要的生物学机制。在骨骼和免疫系统中,巨噬细胞具有显著的细胞融合潜能,在正常过程和疾病期间,它们与其他细胞以及彼此之间融合的倾向就证明了这一点。巨噬细胞融合对于负责骨吸收的多核破骨细胞的正常发育至关重要。来自各种组织区室的巨噬细胞也会融合形成MGC,这是肉芽肿性炎症的一个标志。迄今为止,巨噬细胞融合的潜在机制仍知之甚少。受体 - 配体相互作用被认为介导这一过程,并且有几条证据表明嘌呤能受体与破骨细胞和MGC的形成有关。值得注意的是,细胞外ATP的P2X7受体在破骨细胞以及与感染、异物反应和无菌性炎症相关的多种类型肉芽肿中表达。通过它们感知细胞外信号和细胞间通讯信使ATP的能力,嘌呤能受体可能有助于导致巨噬细胞融合的细胞间相互作用。

相似文献

1
Purinergic signaling in giant cell formation.巨细胞形成中的嘌呤能信号传导。
Front Biosci (Elite Ed). 2012 Jan 1;4(1):41-55. doi: 10.2741/359.
2
Involvement of the purinergic P2X7 receptor in the formation of multinucleated giant cells.嘌呤能P2X7受体在多核巨细胞形成中的作用。
J Immunol. 2006 Nov 15;177(10):7257-65. doi: 10.4049/jimmunol.177.10.7257.
3
ATP downregulates P2X7 and inhibits osteoclast formation in RAW cells.三磷酸腺苷(ATP)下调P2X7并抑制RAW细胞中的破骨细胞形成。
Am J Physiol Cell Physiol. 2004 Aug;287(2):C403-12. doi: 10.1152/ajpcell.00361.2003. Epub 2004 Apr 7.
4
P2X7 receptor drives osteoclast fusion by increasing the extracellular adenosine concentration.P2X7 受体通过增加细胞外腺苷浓度促进破骨细胞融合。
FASEB J. 2011 Apr;25(4):1264-74. doi: 10.1096/fj.10-169854. Epub 2011 Jan 13.
5
ATP receptors and giant cell formation.ATP 受体与巨细胞形成。
J Leukoc Biol. 1999 Nov;66(5):723-6. doi: 10.1002/jlb.66.5.723.
6
[Human monocyte-derived multinucleated giant cells].[人单核细胞来源的多核巨细胞]
Nihon Hansenbyo Gakkai Zasshi. 2004 Sep;73(3):245-51. doi: 10.5025/hansen.73.245.
7
Blockade of the pore-forming P2X7 receptor inhibits formation of multinucleated human osteoclasts in vitro.对形成孔道的P2X7受体的阻断在体外抑制人多核破骨细胞的形成。
Calcif Tissue Int. 2003 Oct;73(4):361-9. doi: 10.1007/s00223-002-2098-y. Epub 2003 Jul 24.
8
Common signalling pathways in macrophage and osteoclast multinucleation.巨噬细胞和破骨细胞多核化的常见信号通路。
J Cell Sci. 2018 Jun 5;131(11):jcs216267. doi: 10.1242/jcs.216267.
9
Spontaneous cell fusion in macrophage cultures expressing high levels of the P2Z/P2X7 receptor.在高表达P2Z/P2X7受体的巨噬细胞培养物中的自发细胞融合。
J Cell Biol. 1997 Aug 11;138(3):697-706. doi: 10.1083/jcb.138.3.697.
10
Lysophosphatidic acid stimulates osteoclast fusion through OC-STAMP and P2X7 receptor signaling.溶血磷脂酸通过 OC-STAMP 和 P2X7 受体信号促进破骨细胞融合。
J Bone Miner Metab. 2014 Mar;32(2):110-22. doi: 10.1007/s00774-013-0470-9. Epub 2013 Apr 27.

引用本文的文献

1
Cellular and microenvironmental cues that promote macrophage fusion and foreign body response.促进巨噬细胞融合和异物反应的细胞和微环境线索。
Front Immunol. 2024 Jul 5;15:1411872. doi: 10.3389/fimmu.2024.1411872. eCollection 2024.
2
Multinucleated Giant Cells: Current Insights in Phenotype, Biological Activities, and Mechanism of Formation.多核巨细胞:表型、生物学活性及形成机制的最新见解
Front Cell Dev Biol. 2022 Apr 11;10:873226. doi: 10.3389/fcell.2022.873226. eCollection 2022.
3
GM-CSF and IL-33 Orchestrate Polynucleation and Polyploidy of Resident Murine Alveolar Macrophages in a Murine Model of Allergic Asthma.
GM-CSF 和 IL-33 协调过敏哮喘小鼠模型中常驻肺泡巨噬细胞的多核化和多倍体化。
Int J Mol Sci. 2020 Oct 11;21(20):7487. doi: 10.3390/ijms21207487.
4
The purinergic receptor P2X5 regulates inflammasome activity and hyper-multinucleation of murine osteoclasts.嘌呤能受体 P2X5 调节炎性体活性和小鼠破骨细胞的过度多核化。
Sci Rep. 2017 Mar 15;7(1):196. doi: 10.1038/s41598-017-00139-2.
5
Molecular Characterization of Macrophage-Biomaterial Interactions.巨噬细胞与生物材料相互作用的分子特征
Adv Exp Med Biol. 2015;865:109-22. doi: 10.1007/978-3-319-18603-0_7.
6
Establishment of c-myc-immortalized Kupffer cell line from a C57BL/6 mouse strain.从C57BL/6小鼠品系建立c-myc永生化库普弗细胞系。
Results Immunol. 2014 Aug 23;4:68-74. doi: 10.1016/j.rinim.2014.08.001. eCollection 2014.
7
Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues.嘌呤能信号在异物反应早期炎症事件中的作用:调节细胞外ATP作为工程植入物和组织的一种赋能技术
Tissue Eng Part B Rev. 2014 Oct;20(5):392-402. doi: 10.1089/ten.TEB.2013.0554. Epub 2014 Jan 16.
8
Purinergic signalling in bone.嘌呤能信号在骨中的作用。
Front Endocrinol (Lausanne). 2012 Sep 19;3:116. doi: 10.3389/fendo.2012.00116. eCollection 2012.
9
P2X7 Receptor Function in Bone-Related Cancer.P2X7受体在骨相关癌症中的功能
J Osteoporos. 2012;2012:637863. doi: 10.1155/2012/637863. Epub 2012 Aug 16.